Gureck Ashley E, Gebrekristos Berkenesh, Turcu Razvan, Kotler Dana, Meleger Alec L
Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital/Harvard Medical School, Boston, MA, USA.
Department of Anesthesiology, Dartmouth Medical School, Hanover, NH, USA.
Interv Pain Med. 2023 Oct 18;2(4):100286. doi: 10.1016/j.inpm.2023.100286. eCollection 2023 Dec.
Previous studies have suggested variability in practice patterns for transforaminal epidural steroid injections (TFESIs) despite published safety guidance. The purpose of this study was to understand recent trends in periprocedural safety practices in TFESIs and how some aspects of interventional pain practice may have been influenced by the coronavirus disease 2019 (COVID-19) pandemic and related supply chain shortages.
A 91-item survey was distributed to 111 program directors of Accreditation Council for Graduate Medical Education accredited Pain Management fellowships, 42 North American Spine Society and Interventional Spine and Musculoskeletal Medicine recognized fellowship directors, and 100 private practice interventional pain physicians to capture current practices in epidural steroid injections from March 2021 to March 2022. Additional responses were obtained through advertising on social media platforms consisting of interventional pain physicians. Cross sectional data from survey responses specific to TFESI-related practices were gathered and analyzed.
Of 103 complete survey responses, 102 physicians perform TFESIs (cervical, 33.3%; thoracic, 40.2%; lumbar, 100%; sacral, 89.2%). There was variability in preprocedural imaging review, sedation practices, contrast and fluoroscopy techniques, and type and dose of steroid preferred. Many physicians saw a decrease in number of procedures performed weekly as a result of the COVID-19 pandemic.
There remains practice variability in various periprocedural aspects of TFESIs despite existing safety recommendations. Further research is needed to identify ongoing barriers to adherence to established guidelines. Recent practice trends may have been affected by unique challenges posed by the COVID-19 pandemic, and these trends should be considered in the event of future supply chain limitations and/or need for disaster response.
先前的研究表明,尽管有已发布的安全指南,但经椎间孔硬膜外类固醇注射(TFESI)的操作模式仍存在差异。本研究的目的是了解TFESI围手术期安全操作的近期趋势,以及介入性疼痛治疗实践的某些方面可能如何受到2019年冠状病毒病(COVID-19)大流行和相关供应链短缺的影响。
向111名获得研究生医学教育认证委员会认可的疼痛管理 fellowship项目主任、42名北美脊柱协会和介入脊柱与肌肉骨骼医学认可的fellowship主任以及100名私人执业介入性疼痛医生发放了一份包含91个条目的调查问卷,以了解2021年3月至2022年3月期间硬膜外类固醇注射的当前操作情况。通过在由介入性疼痛医生组成的社交媒体平台上做广告获得了更多回复。收集并分析了针对TFESI相关操作的调查问卷回复中的横断面数据。
在103份完整的调查问卷回复中,102名医生进行TFESI(颈椎,33.3%;胸椎,40.2%;腰椎,100%;骶椎,89.2%)。术前影像检查、镇静操作、造影剂和透视技术以及首选类固醇的类型和剂量存在差异。许多医生由于COVID-19大流行,每周进行的手术数量有所减少。
尽管有现有的安全建议,但TFESI的各个围手术期方面仍存在操作差异。需要进一步研究以确定遵守既定指南的持续障碍。近期的操作趋势可能受到COVID-19大流行带来的独特挑战的影响,在未来出现供应链限制和/或需要应对灾难时应考虑这些趋势。